GGrantIndex
← Leaderboards

Raymond P Perez

Dartmouth College

$3,553,952
Attributed
$3,553,952
Total exposure
7
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $549.6K · FY200514
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14

Funding mix

By agency

NIH$3,553,952 · 7

By mechanism

P30$1,700,848 · 3
R21$1,203,484 · 3
K24$649,620 · 1

Top collaborators

No co-investigators on record.

Most similar at Dartmouth College

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research

Research focus

Clinical ResearchBaseClinical TrialsResearch PersonnelProtocols DocumentationCancer CenterMonitorReportingSafetyClinical Trials Data Monitoring CommitteesCancer Center Support GrantPrincipal InvestigatorAdverse EventEnrollmentPharmaceutical PreparationsMelanomaNeoplasm /Cancer ChemotherapyPhase Iii Clinical TrialsEnsureHuman SubjectDatabasesFundingHuman Therapy EvaluationAnticancer Research

Grant awards (29)

DATA AND SAFETY MONITORING$124,348
P30 · FY2014 · CA · contact PI
PROTOCOL-SPECIFIC RESEARCH SUPPORT$124,348
P30 · FY2014 · CA · contact PI
PROTOCOL-SPECIFIC RESEARCH SUPPORT$113,018
P30 · FY2013 · CA · contact PI
DATA AND SAFETY MONITORING$25,659
P30 · FY2013 · CA · contact PI
PROTOCOL-SPECIFIC RESEARCH SUPPORT$120,685
P30 · FY2012 · CA · contact PI
DATA AND SAFETY MONITORING$27,310
P30 · FY2012 · CA · contact PI
PROTOCOL-SPECIFIC RESEARCH SUPPORT$119,702
P30 · FY2011 · CA · contact PI
DATA AND SAFETY MONITORING$27,181
P30 · FY2011 · CA · contact PI
Inhibition of S14 by Conjugated Linoleic Acid in Advanced Solid Tumor Patients$208,560
R21 · FY2010 · CA · contact PI
PROTOCOL-SPECIFIC RESEARCH SUPPORT$136,317
P30 · FY2010 · CA · contact PI
SPRY2 predicts survival post-chemotherapy in advanced ovarian cancer.$87,339
R21 · FY2010 · CA · contact PI
SPRY2 predicts survival post-chemotherapy in advanced ovarian cancer.$86,461
R21 · FY2010 · CA · contact PI
DATA AND SAFETY MONITORING$30,954
P30 · FY2010 · CA · contact PI
Inhibition of S14 by Conjugated Linoleic Acid in Advanced Solid Tumor Patients$208,560
R21 · FY2009 · CA · contact PI
SPRY2 predicts survival post-chemotherapy in advanced ovarian cancer.$173,974
R21 · FY2009 · CA · contact PI
PROTOCOL-SPECIFIC RESEARCH SUPPORT$128,026
P30 · FY2009 · CA · contact PI
DATA AND SAFETY MONITORING$29,070
P30 · FY2009 · CA · contact PI
Clinical Research$217,912
P30 · FY2008 · CA · contact PI
Clinical Research$205,362
P30 · FY2007 · CA · contact PI
Clinical Research$93,001
P30 · FY2006 · CA · contact PI
Clinical Research$90,293
P30 · FY2005 · CA
MODULATION OF CLINICAL SENSITIVITY TO CHEMOTHERAPY$129,924
K24 · FY2004 · CA
Clinical Research$87,662
P30 · FY2004 · CA
Atorvastatin, a prenylation inhibitor in acute leukemia.$213,202
R21 · FY2003 · CA
MODULATION OF CLINICAL SENSITIVITY TO CHEMOTHERAPY$129,924
K24 · FY2003 · CA
Atorvastatin, a prenylation inhibitor in acute leukemia.$225,388
R21 · FY2002 · CA
MODULATION OF CLINICAL SENSITIVITY TO CHEMOTHERAPY$129,924
K24 · FY2002 · CA
MODULATION OF CLINICAL SENSITIVITY TO CHEMOTHERAPY$129,924
K24 · FY2001 · CA
MODULATION OF CLINICAL SENSITIVITY TO CHEMOTHERAPY$129,924
K24 · FY2000 · CA